Advancements in treatment of BRAF V600E-mutant metastatic colorectal cancer
10.12354/j.issn.1000-8179.2024.20240046
- VernacularTitle:BRAF V600E型转移性结直肠癌治疗进展
- Author:
Meng LINGHUA
1
;
Pan LIHUA
;
Li RUIDONG
;
Sun LIJUN
;
Ye SHUCHENG
Author Information
1. 济宁医学院附属医院肿瘤科(山东省济宁市 272100)
- Keywords:
metastatic colorectal cancer(mCRC);
BRAF V600E;
first-line treatment;
molecular targeted therapy;
immunotherapy
- From:
Chinese Journal of Clinical Oncology
2024;51(4):209-213
- CountryChina
- Language:Chinese
-
Abstract:
Approximately 8%to 15%of patients with metastatic colorectal cancer(mCRC)harbor BRAF mutation,and the V600E mutation is the most common form of BRAF mutation.The prognosis of patients with metastatic colorectal cancer harboring BRAF V600E mutation is poor.Initial standard chemotherapy is often ineffective,necessitating an intensive follow-up treatment,which usually provides limited effic-acy.Consequently,the disease becomes notably difficult to treat and progresses rapidly,resulting in a decreased overall patient survival rate.This review details the research advancements in treatment of BRAF V600E-mutant metastatic colorectal cancer.
